Healthcare Business Review: Vivus DISSED By Citron, Lundbeck, et al Have OPPORTUNITY

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Here are Thursday’s top stories:

Shares of Vivus, Inc. (NASDAQ:VVUS) decline notably, as investors with long memories, along with a cautious report from Citron Research, view the situation as similar to that of Nitromed eight years ago. The analyst says that the firm’s VVUS’ intellectual property protection seems to be “riddled with flaws” and it’s surprised by the lack of observation on the Street regarding the issue.

Featured Reading: Vivus APPLAUDED! FDA Approves Second Diet Drug in a Month>>

A new generation of drugs that treat schizophrenia could be on the horizon for such firms as H. Lundbeck A/S (HLUKF.PK), Targacept, Inc. (NASDAQ:TRGT), Bioline Rx, Ltd. (NASDAQ:BLRX) and Addex Therapeutics (ADDXF.PK), as SA author Tiran Rothman contends that present treatment for the illness are at best inadequate. Studies show that fewer than 50 percent of patients respond well to the drugs, and 20 percent do not respond at all. In addition, a patent cliff helps to guarantee an opportunity for firms who can develop the next generation of medicines.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business